711 related articles for article (PubMed ID: 25483672)
21. EV71 vaccines: a first step towards multivalent hand, foot and mouth disease vaccines.
Klein MH
Expert Rev Vaccines; 2015 Mar; 14(3):337-40. PubMed ID: 25536888
[TBL] [Abstract][Full Text] [Related]
22. Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71.
Wang X; Dong K; Long M; Lin F; Gao Z; Wang L; Zhang Z; Chen X; Dai Y; Wang H; Zhang H
Arch Virol; 2018 Jul; 163(7):1851-1861. PubMed ID: 29582164
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of bivalent versus monovalent vaccines against hand, foot and mouth disease.
Liu D; Leung K; Jit M; Yu H; Yang J; Liao Q; Liu F; Zheng Y; Wu JT
Clin Microbiol Infect; 2020 Mar; 26(3):373-380. PubMed ID: 31279839
[TBL] [Abstract][Full Text] [Related]
24. A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71.
Xu L; He D; Yang L; Li Z; Ye X; Yu H; Zhao H; Li S; Yuan L; Qian H; Que Y; Kuo Shih JW; Zhu H; Li Y; Cheng T; Xia N
Sci Rep; 2015 Aug; 5():12973. PubMed ID: 26243660
[TBL] [Abstract][Full Text] [Related]
25. Chimeric enterovirus 71 virus-like particle displaying conserved coxsackievirus A16 epitopes elicits potent immune responses and protects mice against lethal EV71 and CA16 infection.
Luo J; Huo C; Qin H; Hu J; Lei L; Pan Z
Vaccine; 2021 Jul; 39(30):4135-4143. PubMed ID: 34116877
[TBL] [Abstract][Full Text] [Related]
26. A Neonatal Murine Model of Coxsackievirus A6 Infection for Evaluation of Antiviral and Vaccine Efficacy.
Zhang Z; Dong Z; Wei Q; Carr MJ; Li J; Ding S; Tong Y; Li D; Shi W
J Virol; 2017 May; 91(9):. PubMed ID: 28250116
[TBL] [Abstract][Full Text] [Related]
27. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus.
Wu Y; Zhu R; Xu L; Li Y; Li S; Yu H; Li S; Zhu H; Cheng T; Xia N
Vaccine; 2017 May; 35(20):2728-2735. PubMed ID: 28408118
[TBL] [Abstract][Full Text] [Related]
28. An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice.
In HJ; Lim H; Lee JA; Kim HJ; Kim JW; Hyeon JY; Yeo SG; Lee JW; Yoo JS; Choi YK; Lee SW
PLoS One; 2017; 12(5):e0178259. PubMed ID: 28542556
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.
Lin CW; Liu CC; Lu TC; Liu SJ; Chow YH; Chong P; Huang MH
Biomed Res Int; 2014; 2014():670506. PubMed ID: 25006583
[TBL] [Abstract][Full Text] [Related]
30. Potential of a bivalent vaccine for broad protection against enterovirus 71 and coxsackie virus 16 infections causing hand, foot, and mouth disease.
Yi EJ; Kim YI; Song JH; Ko HJ; Ahn SH; Lee HJ; Suh B; Yu J; Park J; Lee YJ; Jung EJ; Chang SY
Vaccine; 2023 Sep; 41(41):6055-6063. PubMed ID: 37648607
[TBL] [Abstract][Full Text] [Related]
31. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection.
Cai Y; Liu Q; Huang X; Li D; Ku Z; Zhang Y; Huang Z
Vaccine; 2013 Apr; 31(18):2215-21. PubMed ID: 23499596
[TBL] [Abstract][Full Text] [Related]
32. Protective effect of enterovirus‑71 (EV71) virus‑like particle vaccine against lethal EV71 infection in a neonatal mouse model.
Cao L; Mao F; Pang Z; Yi Y; Qiu F; Tian R; Meng Q; Jia Z; Bi S
Mol Med Rep; 2015 Aug; 12(2):2473-80. PubMed ID: 25936344
[TBL] [Abstract][Full Text] [Related]
33. Immunological evaluation and comparison of different EV71 vaccine candidates.
Chou AH; Liu CC; Chang JY; Lien SP; Guo MS; Tasi HP; Hsiao KN; Liu SJ; Sia C; Wu SC; Lee MS; Hsiao CH; Wang JR; Chow YH; Chong P
Clin Dev Immunol; 2012; 2012():831282. PubMed ID: 23008736
[TBL] [Abstract][Full Text] [Related]
34. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease.
Lim H; In HJ; Lee JA; Sik Yoo J; Lee SW; Chung GT; Choi YK; Chung JK; Cho SJ; Lee JW
Vaccine; 2018 Jun; 36(24):3445-3452. PubMed ID: 29739716
[TBL] [Abstract][Full Text] [Related]
35. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
[TBL] [Abstract][Full Text] [Related]
36. A safety study of inactivated Enterovirus 71 vaccine.
Zhou XB; Lu JJ; Jiang YS; Huo Y; Wang JF; Zhou KF; Li B
Hum Vaccin Immunother; 2013 Jul; 9(7):1430-7. PubMed ID: 23571172
[TBL] [Abstract][Full Text] [Related]
37. Production of EV71 vaccine candidates.
Chong P; Hsieh SY; Liu CC; Chou AH; Chang JY; Wu SC; Liu SJ; Chow YH; Su IJ; Klein M
Hum Vaccin Immunother; 2012 Dec; 8(12):1775-83. PubMed ID: 22992566
[TBL] [Abstract][Full Text] [Related]
38. Coxsackievirus A16-like particles produced in Pichia pastoris elicit high-titer neutralizing antibodies and confer protection against lethal viral challenge in mice.
Zhang C; Liu Q; Ku Z; Hu Y; Ye X; Zhang Y; Huang Z
Antiviral Res; 2016 May; 129():47-51. PubMed ID: 26902108
[TBL] [Abstract][Full Text] [Related]
39. Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys.
In HJ; Lim H; Lee JA; Lee SR; Jin YB; Jeong KJ; Hyeon JY; Yoo JS; Lee JW; Choi YK; Lee SW
PLoS One; 2018; 13(10):e0202552. PubMed ID: 30278051
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally.
Fan S; Liao Y; Jiang G; Wang L; Zhao H; Yu L; Xu X; Li D; Zhang Y; Li Q
Vaccine; 2021 Jan; 39(3):596-604. PubMed ID: 33342637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
